634 Mode of action and resistance studies unveil new roles for tropodithietic acid as an anticancer agent and the γ-glutamyl cycle as a proton sink.
http://www.pnas.org/content/113/6/1630.abstract
633 Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
http://stm.sciencemag.org/content/8/325/325ra17.abstract?_ga=1.44396972.901395532.1409089406
632 An oligoclonal antibody overcomes drug resistance in colorectal cancers with EGFR mutations.
http://stm.sciencemag.org/content/8/324/324ra14
631 Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.
http://www.nature.com/ncomms/2016/160202/ncomms10391/full/ncomms10391.html
630 Therapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.
http://www.nature.com/ncomms/2016/160202/ncomms10593/full/ncomms10593.html
629 Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.
http://www.pnas.org/content/113/4/1050.abstract
628 A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.
http://science.sciencemag.org/content/351/6272/aad2197.abstract
627 Structural details of how oncogenic human papilloma viruses induce cancer by targeting the tumour suppressor p53 for ubiquitin-mediated degradation.
http://www.nature.com/nature/journal/v529/n7587/full/nature16481.html
626 SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.
http://www.pnas.org/content/113/3/638.abstract
625 Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis.
http://www.pnas.org/content/113/3/E328.abstract
624 Bioengineered yeast-derived vacuoles with enhanced tissue-penetrating ability for targeted cancer therapy.
http://www.pnas.org/content/113/3/710.abstract
623 Targeting NF-κB in glioblastoma: A therapeutic approach.
http://advances.sciencemag.org/content/2/1/e1501292
622 In vivo covalent cross-linking of photon-converted rare-earth nanostructures for tumour localization and theranostics.
http://www.nature.com/ncomms/2016/160120/ncomms10432/full/ncomms10432.html
621 An ID2-dependent mechanism for VHL inactivation in cancer.
http://www.nature.com/nature/journal/v529/n7585/full/nature16475.html
620 Substantial contribution of extrinsic risk factors to cancer development.
http://www.nature.com/nature/journal/v529/n7584/full/nature16166.html
619 Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.
http://www.nature.com/nature/journal/v529/n7584/full/nature16466.html
618 Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients.
http://stke.sciencemag.org/content/8/408/ra130.abstract
617 Accumulation of differentiating intestinal stem cell progenies drives tumorigenesis.
http://www.nature.com/ncomms/2015/151222/ncomms10219/full/ncomms10219.html
616 Therapeutic targeting of casein kinase 1δ in breast cancer.
http://stm.sciencemag.org/content/7/318/318ra202
615 A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing.
http://www.nature.com/ncomms/2015/151209/ncomms10001/full/ncomms10001.html
|
